Manfredi Rizzo is former Director, Clinical Medical & Regulatory Department, Novo Nordisk Europe East and South and has given lectures, received honoraria and research support, and participated in conferences, advisory boards and clinical trials sponsored by pharmaceutical industry including Amgen, AstraZeneca, Boehringer Ingelheim, Kowa, Eli Lilly, Meda, Mylan, Merck Sharp & Dohme, Novo Nordisk, Novartis, Roche Diagnostics, Sanofi and Servier
We expect in the near future growing recognition of GSH involvement, by S -glutathionylation and/or by the thiols redox state shift, not only in the induction of ATG and/or apoptosis, but also in the modulation of activities of molecular/transcription factors such as NEF2L2, PGC1, and p53 that by inducing the antioxidant defense and assuring mitochondrial homeostasis could block both processes
A Prime Therapeutics analysis (2024) found GLP-1 use raised annual healthcare costs by 46% for obese patients in two years versus controls ( [71] ), mainly driven by drug spending
GLP-1 medications such as Tirzepatide and Semaglutide work by reducing appetite, controlling cravings, improving fullness, and helping the body use energy more efficiently leading to steady, sustainable fat loss without restrictive diets or surgery